Dopamine-hypocretin/orexin interactions the prefrontal cortex and schizophrenia

Hypocretins: Integrators of Physiological Functions

Volumn , Issue , 2005, Pages 339-351

  Deutch, Ariel Y ^a   Fadel, Jim ^b   Bubser, Michael ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919835747     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-25446-3_23     Document Type: Chapter

References (72)

1. L. De Lecea, T. S. Kilduff, C. Peyron, X. Gao, P. E. Foye, P. E. Danielson, C. Fukuhara, E. L. Battenberg, V. T. Gautvik, F. S. Bartlett, 2nd, W. N. Frankel, A. N. Van Den Pol, F. E. Bloom, K. M. Gautvik and J. G. Sutcliffe, The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc Natl Acad Sci U S A 95, 322-327 (1998).
2. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams, J. A. Richarson, G. P. Kozlowski, S. Wilson, J. R. Arch, R. E. Buckingham, A. C. Haynes, S. A. Carr, R. S. Annan, D. E. McNulty, W. S. Liu, J. A. Terrett, N. A. Elshourbagy, D. J. Bergsma and M. Yanagisawa, Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior, Cell 92, 573-585 (1998).
3. C. Peyron, D. K. Tighe, A. N. Van Den Pol, L. De Lecea, H. C. Heller, J. G. Sutcliffe and T. S. Kilduff, Neurons containing hypocretin (orexin) project to multiple neuronal systems, J Neurosci 18, 9996-10015 (1998).
4. T. Nambu, T. Sakurai, K. Mizukami, Y. Hosoya, M. Yanagisawa and K. Goto, Distribution of orexin neurons in the adult rat brain, Brain Res 827, 243-260 (1999).
5. S. D. Iversen, in: Behavioural effects of manipulation of basal ganglia neurotransmitters, edited by D. Evered and M. O'Connor (Ciba Foundation, Pitman, 1984), pp. 183-200.
6. O. T. Phillipson, Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat, J Comp Neurol 187, 117-143 (1979).
7. J. Fadel and A. Y. Deutch, Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area, Neuroscience 111, 379-387 (2002).
8. T. Hokfelt, R. Martensson, A. Bjorklund, S. Kleinau and M. Goldstein, in: Distributional maps of tyrosine hydroxylase-immunoreactive neurons in the rat brain, edited by A. Bjorklund and T. Hokfelt (Elsevier, Amsterdam, 1984), pp. 277-379.
9. A. Y. Deutch, A. J. Bourdelais and D. S. Zahm, in: The nucleus accumbens core and shell: accumbal compartments and their functional attributes, edited by P. W. Kalivas and C. D. Barnes (CRC Press, Baton Rouge, LA, 1993), pp. 45-88.
10. M. Yoshida, M. Shirouzu, M. Tanaka, K. Semba and H. C. Fibiger, Dopaminergic neurons in the nucleus raphe dorsalis innervate the prefrontal cortex in the rat: a combined retrograde tracing and immunohistochemical study using anti-dopamine serum, Brain Res 496, 373-376 (1989).
11. S. R. Sesack, A. Y. Deutch, R. H. Roth and B. S. Bunney, Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin, J Comp Neurol 290, 213-242 (1989).
12. A. Y. Deutch, in: Sites and mechanisms of action of antipsychotic drugs as revealed by immediate-early gene expression, edited by J. G. Csernansky (Springer, Berlin, 1996), pp. 117-161.
13. A. N. Van Den Pol, P. K. Ghosh, R. J. Liu, Y. Li, G. K. Aghajanian and X. B. Gao, Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus, J Physiol 541, 169-185 (2002).
14. Y. Li, X. B. Gao, T. Sakurai and A. N. Van Den Pol, Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system, Neuron 36, 1169-1181 (2002).
15. J. Fadel, M. Bubser and A. Y. Deutch, Differential activation of orexin neurons by antipsychotic drugs associated with weight gain, J Neurosci 22, 6742-6746 (2002).
16. B. A. Baldo, L. Gual-Bonilla, K. Sijapati, R. A. Daniel, C. F. Landry and A. E. Kelley, Activation of a subpopulation of orexin/hypocretin-containing hypothalamic neurons by GABAA receptor-mediated inhibition of the nucleus accumbens shell, but not by exposure to a novel environment, Eur J Neurosci 19, 376-386 (2004).
17. D. S. Zahm, S. L. Jensen, E. S. Williams and J. R. Martin, 3rd, Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell, Eur J Neurosci 11, 1119-1126 (1999).
18. M. Hakansson, L. De Lecea, J. G. Sutcliffe, M. Yanagisawa and B. Meister, Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus, J Neuroendocrinol 11, 653-663 (1999).
19. D. B. Allison, J. L. Mentore, M. Heo, L. P. Chandler, J. C. Cappelleri, M. C. Infante and P. J. Weiden, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry 156, 1686-1696 (1999).
20. J. T. Willie, R. M. Chemelli, C. M. Sinton and M. Yanagisawa, To eat or to sleep? Orexin in the regulation of feeding and wakefulness, Annu Rev Neurosci 24, 429-458 (2001).
21. D. Smart and J. Jerman, The physiology and pharmacology of the orexins, Pharmacol Ther 94, 51-61 (2002).
22. Y. Date, Y. Ueta, H. Yamashita, H. Yamaguchi, S. Matsukura, K. Kangawa, T. Sakurai, M. Yanagisawa and M. Nakazato, Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems, Proc Natl Acad Sci U S A 96, 748-753 (1999).
23. J. Arnt, Pharmacological differentiation of classical and novel antipsychotics, Int Clin Psychopharmacol 13 Suppl 3, S7-14 (1998).
24. A. Y. Deutch, B. Moghaddam, R. B. Innis, J. H. Krystal, G. K. Aghajanian, B. S. Bunney and D. S. Charney, Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia, Schizophr Res 4, 121-156 (1991).
25. J. Q. Wang, A. J. Smith and J. F. McGinty, A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain, Neuroscience 68, 83-95 (1995).
26. B. Johansson, K. Lindstrom and B. B. Fredholm, Differences in the regional and cellular localization of cfos messenger RNA induced by amphetamine, cocaine and caffeine in the rat, Neuroscience 59, 837-849 (1994).
27. G. S. Robertson and H. C. Fibiger, Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine, Neuroscience 46, 315-328 (1992).
28. A. Y. Deutch and R. S. Duman, The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization, Neuroscience 70, 377-389 (1996).
29. J. S. Lamberti, T. Bellnier and S. B. Schwarzkopf, Weight gain among schizophrenic patients treated with clozapine, Am J Psychiatry 149, 689-690 (1992).
30. R. Leadbetter, M. Shutty, D. Pavalonis, V. Vieweg, P. Higgins and M. Downs, Clozapine-induced weight gain: prevalence and clinical relevance, Am J Psychiatry 149, 68-72 (1992).
31. H. Y. Meltzer, E. Perry and K. Jayathilake, Clozapine-induced weight gain predicts improvement in psychopathology, Schizophr Res 59, 19-27 (2003).
32. A. Abi-Dargham and H. Moore, Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia, Neuroscientist 9, 404-416 (2003).
33. T. S. Braver, D. M. Barch and J. D. Cohen, Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function, Biol Psychiatry 46, 312-328 (1999).
34. J. D. Jentsch, R. H. Roth and J. R. Taylor, Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action, Prog Brain Res 126, 433-453 (2000).
35. K. D. Youngren, B. Moghaddam, B. S. Bunney and R. H. Roth, Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment, Neurosci Lett 165, 41-44 (1994).
36. B. Moghaddam and B. S. Bunney, Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study, J Neurochem 54, 1755-1760 (1990).
37. S. K. Bhat and R. Galang, Narcolepsy presenting as schizophrenia,] Am J Psychiatry 159, 1245 (2002).
38. A. B. Douglass, P. Hays, F. Pazderka and J. M. Russell, Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy, J Nerv Ment Dis 179, 12-17; discussion 18 (1991).
39. A. B. Douglass, J. E. Shipley, R. F. Haines, R. C. Scholten, E. Dudley and A. Tapp, Schizophrenia, narcolepsy, and HLA-DR15, DQ6, Biol Psychiatry 34, 773-780 (1993).
40. A. Vourdas, J. M. Shneerson, C. A. Gregory, I. E. Smith, M. A. King, E. Morrish and P. J. McKenna, Narcolepsy and psychopathology: is there an association?, Sleep Med 3, 353-360 (2002).
41. S. S. Chakravorty and D. B. Rye, Narcolepsy in the older adult: epidemiology, diagnosis and management, Drugs Aging 20, 361-376 (2003).
42. G. J. Lammers and S. Overeem, Pharmacological management of narcolepsy, Expert Opin Pharmacother 4, 1739-46 (2003).
43. M. M. Mitler and R. Hayduk, Benefits and risks of pharmacotherapy for narcolepsy, Drug Saf 25, 791-809 (2002).
44. T. E. Scammell, The neurobiology, diagnosis, and treatment of narcolepsy, Ann Neurol 53, 154-166 (2003).
45. S. Overeem, T. E. Scammell and G. J. Lammers, Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy, Curr Opin Neurol 15, 739-745 (2002).
46. Z. L. Huang, W. M. Qu, W. D. Li, T. Mochizuki, N. Eguchi, T. Watanabe, Y. Urade and O. Hayaishi, Arousal effect of orexin A depends on activation of the histaminergic system, Proc Natl Acad Sci U S A 98, 9965-9970 (2001).
47. T. E. Scammell, I. V. Estabrooke, M. T. McCarthy, R. M. Chemelli, M. Yanagisawa, M. S. Miller and C. B. Saper, Hypothalamic arousal regions are activated during modafinil-induced wakefulness, J Neurosci 20, 8620-8628 (2000).
48. S. Fulda and H. Schulz, Cognitive dysfunction in sleep disorders, Sleep Med Rev 5, 423-445 (2001).
49. A. Naumann, J. Bierbrauer, H. Przuntek and I. Daum, Attentive and preattentive processing in narcolepsy as revealed by event-related potentials (ERPs), Neuroreport 12, 2807-2811 (2001).
50. A. Naumann and I. Daum, Narcolepsy: pathophysiology and neuropsychological changes, Behav Neurol 14, 89-98 (2003).
51. M. Rieger, G. Mayer and S. Gauggel, Attention deficits in patients with narcolepsy, Sleep 26, 36-43 (2003).
52. H. Schulz and J. Wilde-Frenz, Symposium: Cognitive processes and sleep disturbances: The disturbance of cognitive processes in narcolepsy, J Sleep Res 4, 10-14 (1995).
53. J. R. De Quardo, Modafinil and antipsychotic-induced sedation, J Clin Psychiatry 65, 278-9; author reply 279 (2004).
54. E. H. Makela, K. Miller and W. D. Cutlip, 2nd, Three case reports of modafinil use in treating sedation induced by antipsychotic medications, J Clin Psychiatry 64, 485-486 (2003).
55. E. Teitelman, Modafinil for narcolepsy, Am J Psychiatry 158, 970-971 (2001).
56. D. C. Randall, J. M. Shneerson, K. K. Plaha and S. E. File, Modafinil affects mood, but not cognitive function, in healthy young volunteers, Hum Psychopharmacol 18, 163-173 (2003).
57. D. C. Turner, T. W. Robbins, L. Clark, A. R. Aron, J. Dowson and B. J. Sahakian, Cognitive enhancing effects of modafinil in healthy volunteers, Psychopharmacology (Berl) 165, 260-269 (2003).
58. M. H. Rosenthal and S. L. Bryant, Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia, Clin Neuropharmacol 27, 38-43 (2004).
59. D. C. Turner, L. Clark, E. Pomarol-Clotet, P. McKenna, T. W. Robbins and B. J. Sahakian, Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia, Neuropsychopharmacology 29, 1363-1373 (2004).
60. R. M. Bilder, R. S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J. P. Lindenmayer, L. Citrome, J. McEvoy, M. Kunz, M. Chakos, T. B. Cooper, T. L. Horowitz and J. A. Lieberman, Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder, Am J Psychiatry 159, 1018-1028 (2002).
61. M. A. Lee, K. Jayathilake and H. Y. Meltzer, A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia, Schizophr Res 37, 1-11 (1999).
62. H. Y. Meltzer and S. R. McGurk, The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia, Schizophr Bull 25, 233-255 (1999).
63. C. A. Tamminga, Similarities and differences among antipsychotics, J Clin Psychiatry 64 Suppl 17, 7-10 (2003).
64. K. L. Davis, R. S. Kahn, G. Ko and M. Davidson, Dopamine in schizophrenia: a review and reconceptualization, Am J Psychiatry 148, 1474-1486 (1991).
65. P. S. Goldman-Rakic, S. A. Castner, T. H. Svensson, L. J. Siever and G. V. Williams, Targeting the dopamine D (1) receptor in schizophrenia: insights for cognitive dysfunction, Psychopharmacology (Berl) 174, 3-16 (2004).
66. D. A. Lewis and J. A. Lieberman, Catching up on schizophrenia: natural history and neurobiology, Neuron 28, 325-334 (2000).
67. C. A. Tamminga and A. Carlsson, Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis, Curr Drug Targets CNS Neurol Disord 1, 141-147 (2002).
68. Z. De Saint Hilaire, M. Orosco, C. Rouch, G. Blanc and S. Nicolaidis, Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats, Neuroreport 12, 3533-353 (2001).
69. J. Fadel and A. Y. Deutch, Orexin regulation of catecholamine release in prefrontal cortex, Soc Neurosci
70. N. M. Vittoz and C. W. Berridge, Hypocretin increases dopamine efflux in rat prefrontal cortex and not nucleus accumbens, Soc Neurosci
71. M. A. Dalal, A. Schuld and T. Pollmacher, Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects, Mol Psychiatry 8, 836-837 (2003).
72. J. D. Elsworth, D. J. Leahy, R. H. Roth and D. E. Redmond, Jr., Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates, J Neural Transm 68, 51-62 (1987).